Chronic resveratrol administration improves diabetic cardiomyopathy in part by reducing oxidative stress

Cardiology Journal

Volumn 21, Issue 1, 2014, Pages 39-46

  Mohammadshahi, Majid ^a   Haidari, Fatemeh ^a   Soufi, Farhad Ghadiri ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HORMOZGAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antioxidant; Cardiomyopathy; Hyperglycemia; Redox status; Resveratrol; Type 2 diabetes

Indexed keywords

8 ISOPROSTANE; GLUCOSE; GLUTATHIONE; GLUTATHIONE DISULFIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; NITRATE; NITRITE; RESVERATROL; SUPEROXIDE DISMUTASE; ANTIOXIDANT; RIBONUCLEOTIDE REDUCTASE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIABETIC CARDIOMYOPATHY; DRUG EFFICACY; ELISA KIT; ENZYME ACTIVITY; HEART VENTRICLE PRESSURE; HEART WEIGHT; HYPERGLYCEMIA; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; RAT; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETIC CARDIOMYOPATHIES; DOSE RESPONSE; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY; RIBONUCLEOTIDE REDUCTASES; STILBENES;

EID: 84894315676     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2013.0051     Document Type: Article

References (31)

1. Falcão-Pires I, Leite-Moreira AF. Diabetic cardiomyopathy: Understanding the molecular and cellular basis to progress in diagnosis and treatment. Heart Fail Rev, 2012; 17: 325-344.
2. Xu YJ, Tappia PS, Neki NS, Dhalla NS. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail Rev, 2014; 19: 113-121.
3. Khullar M, Al-Shudiefat AA, Ludke A, Binepal G, Singal PK. Oxidative stress: A key contributor to diabetic cardiomyopathy. Can J Physiol Pharmacol, 2010; 88: 233-240.
4. Csiszar A. Anti-inflammatory effects of resveratrol: Possible role in prevention of age-related cardiovascular disease. Ann N Y Acad Sci, 2011; 1215: 117-122.
5. Turan B, Tuncay E, Vassort G. Resveratrol and diabetic cardiac function: Focus on recent in vitro and in vivo studies. J Bioenerg Biomembr, 2012; 44: 281-296.
6. Dekkers DH, Bezstarosti K, Gurusamy N et al. Identification by a differential proteomic approach of the induced stress and redox proteins by resveratrol in the normal and diabetic rat heart. J Cell Mol Med, 2008; 12: 1677-1689.
7. Thirunavukkarasu M, Penumathsa SV, Koneru S et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med, 2007; 43: 720-229.
8. Penumathsa SV, Thirunavukkarasu M, Zhan L et al. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J Cell Mol Med, 2008; 12: 2350-2361.
9. Zhang H, Morgan B, Potter BJ et al. Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging. Am J Physiol Heart Circ Physiol, 2010; 299: H985-H994.
10. Delucchi F, Berni R, Frati C et al. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS One, 2012; 7: e39836.
11. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol, 2010; 8: e1000412.
12. Soufi FG, Vardyani M, Sheervalilou R, Mohammadi M, Somi MH. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen Physiol Biophys, 2012; 31: 431-438.
13. Palsamy P, Subramanian S. Resveratrol, a natural phytoalexin, norma lizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed Pharmacother, 2008; 62: 598-605.
14. Soufi FG, Saber MM, Ghiassie R, Alipour M. Role of 12-week resistance training in preserving the heart against ischemia-reperfusion-induced injury. Cardiol J, 2011; 18: 140-145.
15. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Euro J harmachol, 2010; 635: 1-8.
16. Lekli I, Szabo G, Juhasz B et al. Protective mechanisms of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: the role of GLUT-4 and endothelin. Am J Physiol Heart Circ Physiol, 2008; 294: H859-H866.
17. Roghani M, Baluchnejadmojarad T. Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats. Phytother Res, 2010; 24: S148-S154.
18. Crandall JP, Oram V, Trandafirescu G et al. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci, 2012; 67: 1307-1312.
19. Brasnyó P, Molnár GA, Mohás M et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr, 2011; 106: 383-389.
20. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res, 2012; 32: 537-541.
21. Poulsen MM, Vestergaard PF, Clasen BF et al. High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2012; 62: 1186-1195.
22. Palsamy P, Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic b-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J Cell Physiol, 2010; 224: 423-432.
23. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. Free Radic Biol Med, 2011; 50: 567-575.
24. Pitocco D, Zaccardi F, Di Stasio E et al. Oxidative stress, nitric oxide, and diabetes. Rev Diabet Stud, 2010; 7: 15-25.
25. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramírez E, Egido J, Tuñón J. Potential role of nuclear factor kB in diabetic cardiomyo pathy. Mediators Inflamm, 2011; 2011: 65 2097.
26. Tomé-Carneiro J, Gonzálvez M, Larrosa M et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol, 2012; 110: 356-363.
27. Magyar K, Halmosi R, Palfi A et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc, 2012; 50: 179-187.
28. Militaru C, Donoiu I, Craciun A, Scorei ID, Bulearca AM, Scorei RI. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: Effects on lipid profiles, inflammation markers, and quality of life. Nutrition, 2013; 29: 178-183.
29. Akar F, Pektas MB, Tufan C et al. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc Drugs Ther, 2011; 25: 119-131.
30. Yun JM, Chien A, Jialal I, Devaraj S. Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: mechanistic insights. J Nutr Biochem, 2012; 23: 699-705.
31. Lee JH, Song MY, Song EK et al. Overexpression of SIRT1 protects pancreatic b-cells against cytokine toxicity by suppressing the nuclear factor-kappa B signaling pathway. Diabetes, 2009; 58: 344-351.